Patient advocacy groups welcome 40% increase in Alzheimer’s NIH research funds authorized by Congress

The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH).

The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), a Washington-based entity launched in 2015 by UsAgainstAlzheimer’s and the Global CEO Initiative (CEOi) on Alzheimer’s Disease. GAP works with leading researchers, drug firms, nonprofit groups and governments to slash the time, cost and risk involved in Alzheimer’s clinical trials and speed up approval of innovative medicines and other therapies.

The foundation aims to build a standing global clinical trial platform of willing participants through novel recruitment techniques, coupled with a network of participating high-performance clinical trial sites.

Read the full article online here or via PDF here.